急性肾功能衰竭治疗药的全球市场 - 2022年～2029年

本报告提供全球急性肾功能衰竭治疗药市场相关调查，市场概要，以及各疾病适应症，各治疗，各终端用户，各地区趋势，竞争情形，及加入此市场的主要企业简介等资讯。

目录

第1章 急性肾功能衰竭治疗药市场调查方法与范围

第2章 急性肾功能衰竭治疗药市场-市场定义和概要

第3章 急性肾功能衰竭治疗药市场-摘要整理

• 各疾病适应症市场明细
• 各治疗市场明细
• 各终端用户市场明细
• 各地区市场明细

第4章 急性肾功能衰竭治疗药市场动态

• 影响市场的要素
  • 促进因素
  • 阻碍因素
  • 市场机会
  • 影响分析

第5章 急性肾功能衰竭治疗药市场-产业分析

• 波特的五力分析
• 供应链分析
• 价格分析
• 法规分析
• 未满足需求

第6章 急性肾功能衰竭治疗药市场-COVID-19分析

• 市场上COVID-19分析
  • COVID-19前的市场情境
  • COVID-19目前市场情境
  • COVID-19后或未来情境
• COVID-19的价格动态
• 需求与供给的频谱
• 大流行时的市场相关的政府的举措
• 製造商策略性举措
• 结论

第7章 急性肾功能衰竭治疗药市场-各疾病适应症

• 简介
• 市场规模分析，及与前一年同期比较成长分析(%)，各疾病适应症
• 各疾病适应症市场魅力指数
  • 肾前肾功能衰竭
  • 肾后肾功能衰竭
  • 内因性肾功能衰竭

第8章 急性肾功能衰竭治疗药市场-各治疗

• 简介
• 市场规模分析，及与前一年同期比较成长分析(%)，各治疗
• 各治疗市场魅力指数
  • 药物疗法
  • 透析
  • 其他

第9章 急性肾功能衰竭治疗药市场-各终端用户

• 简介
  • 市场规模分析，及与前一年同期比较成长分析(%)，各终端用户
  • 各终端用户市场魅力指数
• 医院
  • 简介
  • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)，2021年～2029年
• 诊所
• 其他

第10章 急性肾功能衰竭治疗药市场-各地区

• 简介
  • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)，2021年～2029年，各地区
  • 各地区的市场魅力指数
• 北美
• 欧洲
• 南美
• 亚太地区
• 中东和非洲

第11章 急性肾功能衰竭治疗药市场-竞争情形

• 主要的发展与策略
• 企业占有率分析
• 产品的基准

第12章 急性肾功能衰竭治疗药市场-企业简介概要

• Fresenius Medical Care
• B. Braun Melsungen AG
• Pfizer Inc.
• Medtronic
• Baxter
• Teleflex Incorporated
• Cook
• Upsher-Smith Laboratories, LLC.
• Dialife SA
• Asahi Kasei Medical Co., Ltd.

第13章 急性肾功能衰竭治疗药市场-DataM

Market Overview

The global acute renal failure therapeutics market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

A condition in which the kidneys lose their ability to filter waste from the bloodstream. When kidneys lose their filtering ability, dangerous levels of waste can build up, and blood's chemical makeup can become unbalanced. Acute kidney failure, also known as acute renal failure or acute kidney injury, occurs quickly, usually within a few days.

Market Dynamics

The factors influencing the global acute renal failure therapeutics market are the increasing research and development and the growing prevalence of acute renal failure.

The increasing research and development is expected to drive the market growth

A condition in which the kidneys lose their ability to filter waste from the bloodstream. When kidneys lose their filtering ability, dangerous levels of waste can build up, and blood's chemical makeup can become unbalanced. Acute kidney failure, also known as acute renal failure or acute kidney injury, occurs quickly, usually within a few days. Early goal-directed therapy aimed at improving renal (and other organs) perfusion has shown to be effective in treating ARF, and tight blood glucose control reduces the need for RRT. Antiendothelin antibodies, oxygen-free radical scavengers, and inhibitors of inducible nitric oxide synthetase are some of the more specific experimental treatments being tested to reduce renal damage caused by sepsis. Renal perfusion may be improved by infusions of atrial natriuretic peptide (ANP) or a synthetic analogue anaritide, and recombinant erythropoietin can reduce ischaemic renal injury in an animal model. Bioartificial kidneys as a renal replacement modality, a combination of a hemofilter and renal tubular cells designed to reduce circulating pro-inflammatory mediators, and possible stem cell therapy to improve native kidney recovery could be therapeutic strategies in the future. AKI is currently treated in a supportive manner. Recent advances in the understanding of renal injury and repair signaling pathways in preclinical models, on the other hand, have enabled the development of a number of promising pharmaceuticals that are currently being tested in human clinical trials. Anti-inflammatory agents (recAP, AB103, ABT-719), antioxidants (iron chelators, Heme Arginate), vasodilators (Levosimendan), apoptosis inhibitors (QPI-1002), and restorative agents (recAP, AB103, ABT-719) are a few examples (THR-184, BB- 3, MSCs). Given the complex multi-factorial pathophysiology of human AKI, any single agent is unlikely to produce a profound and consistent beneficial response. Any future pharmacotherapy for AKI is expected to be individualised based on the aetiology and primary mechanism of action. Different combinations of agents will most likely be required for different clinical scenarios.

Lack of knowledge of acute renal failure is expected to hamper the market growth

Some people's kidneys suddenly stop working. The kidneys abruptly stop performing their vital functions of excreting excess fluid and salts and removing waste. When the kidneys go on strike, the body accumulates dangerous levels of fluid, salts, and wastes. The person's life is jeopardised without functioning kidneys.

This condition is known as acute (sudden) kidney failure. The kidneys of most people with chronic kidney failure gradually lose function. On the other hand, acute kidney failure develops rapidly over a few hours or days in people who have it. Those who have already been admitted to a hospital or are critically ill and require intensive care are considered high risk. Acute kidney failure is almost always caused by another medical condition, an infection, or the use of kidney-harming medications. A variety of factors can cause kidney damage. A number of other serious conditions can exacerbate acute kidney failure.

COVID-19 Impact Analysis

In intensive care units (ICUs), 20 to 25 percent of patients with acute kidney injury (AKI) require renal replacement therapy (RRT). In the ICU, the mortality rate for patients with AKI requiring dialysis (AKI-RRT) is greater than 50%, which can be explained by the recent increase in age and the burden of comorbidities in critically ill patients. The COVID-19 pandemic, caused by the new coronavirus SARS-CoV-2, significantly impacted nephrology practice, resulting in increased demand for nephrologists and nephrology-specialized nurses RRT equipment and supplies. Knowing the incidence, characteristics, and outcomes of AKI linked to COVID-19 is critical for health planning. Hence, COVID-19 is expected to positively impact the global acute renal failure therapeutics market.

Segment Analysis

Pre-renal Kidney Failure segment is expected to dominate the market growth

Prerenal AKI is a well-studied condition requiring early detection and treatment to avoid long-term consequences. The epidemiology, evaluation, and management of prerenal acute kidney injury are covered in this activity. It also explains how the interprofessional team can help patients with this condition get better care. Prerenal renal failure is caused by poor nephron perfusion, which results in a decrease in GFR. It stems from an imbalance in the delivery of nutrition and oxygen to the nephrons during increased energy demand. As a result, any condition that affects the systemic circulation or reduces renal perfusion can impair GFR. Autoregulatory functions are present in a healthy person, which aid in maintaining the GFR. However, these autoregulatory mechanisms may be insufficient to boost GFR in patients with a history of chronic kidney disease (CKD). Intravascular volume depletion, hypotension, sepsis, shock, over diuresis, heart failure, cirrhosis, bilateral renal artery stenosis/single functioning kidney, which is worsened by angiotensin-converting enzyme (ACE) inhibitors and other drugs (i.e., non-steroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, diuretics, etc.) are just a few of the causes.

Geographical Analysis

North America region is expected to hold the largest market share in the global acute renal failure therapeutics market

Governments are increasingly pursuing research and development initiatives in the healthcare sector. In addition, a number of government agencies are planning to hold public awareness campaigns about infant healthcare. Such initiatives will eventually gain a lot of traction and are expected to drive market growth in this region. Companies are increasingly investing in acute renal failure treatment options. Strategic collaborations, the development of technologically advanced drugs, and acquisitions are some of the strategies used by key players to strengthen their market position. For instance, Mayo Clinic and Baxter International teamed up to create a renal care centre in the United States. This new centre of excellence will focus on patients with acute renal failure to improve patient outcomes.

Competitive Landscape

The global acute renal failure therapeutics market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Fresenius Medical Care, B. Braun Melsungen AG, Pfizer Inc., Medtronic, Baxter, Teleflex Incorporated, Cook., Upsher-Smith Laboratories, LLC. , Dialife SA, Asahi Kasei Medical Co., Ltd.

Fresenius Medical Care

Overview: Fresenius Medical Care AG & Co. KGaA is a German healthcare company that provides dialysis services to patients through outpatient dialysis centers. The company primarily treats patients with end-stage renal disease (ESRD). The company has headquarters in Germany. And was founded in 1996.

Product Portfolio: Continuous renal replacement therapy (CRRT) uses special solutions and filters to clean the blood, mimicking the kidney's natural functions and maintaining body fluid levels. Fresenius Medical Care provides effective acute kidney injury treatment using a variety of therapies tailored to each patient's specific needs.

Why Purchase the Report?

• Visualize the composition of the global acute renal failure therapeutics market segmentation by disease indication, treatment, and end user, highlighting the key commercial assets and players.

• Identify commercial opportunities in global acute renal failure therapeutics market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of global acute renal failure therapeutics market- level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global acute renal failure therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Table of Contents

1. Acute Renal Failure Therapeutics MarketMethodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Acute Renal Failure Therapeutics Market- Market Definition and Overview

3. Acute Renal Failure Therapeutics Market- Executive Summary

• 3.1. Market Snippet By Disease Indication
• 3.2. Market Snippet By Treatment
• 3.3. Market Snippet By End User
• 3.4. Market Snippet By Region

4. Acute Renal Failure Therapeutics Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The increasing research and development
  • 4.1.2. Restraints:
    • 4.1.2.1. Lack of knowledge of acute renal failure
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Acute Renal Failure Therapeutics Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Acute Renal Failure Therapeutics Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Acute Renal Failure Therapeutics Market- By Disease Indication

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
• 7.3. Market Attractiveness Index, By Disease Indication
  • 7.3.1. Pre-renal Kidney Failure
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Post-renal Kidney Failure
  • 7.3.3. Intrinsic Kidney Failure

8. Acute Renal Failure Therapeutics Market-By Treatment

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
• 8.3. Market Attractiveness Index, By Treatment
  • 8.3.1. Medications/ Drug Therapy
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3.2. Dialysis
  • 8.3.3. Others

9. Acute Renal Failure Therapeutics Market- By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Clinics
• 9.4. Other

10. Acute Renal Failure Therapeutics Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Acute Renal Failure Therapeutics Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Acute Renal Failure Therapeutics Market- Company Profiles

• 12.1. Fresenius Medical Care*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. B. Braun Melsungen AG
• 12.3. Pfizer Inc.
• 12.4. Medtronic
• 12.5. Baxter
• 12.6. Teleflex Incorporated
• 12.7. Cook
• 12.8. Upsher-Smith Laboratories, LLC.
• 12.9. Dialife SA
• 12.10. Asahi Kasei Medical Co., Ltd.

LIST NOT EXHAUSTIVE

13. Acute Renal Failure Therapeutics Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us